Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 12,691 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total value of $135,032.24. Following the completion of the transaction, the chief executive officer now directly owns 5,857,603 shares of the company’s stock, valued at $62,324,895.92. The trade was a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 26th, Patrick Miles sold 32,393 shares of Alphatec stock. The stock was sold at an average price of $10.89, for a total transaction of $352,759.77.
• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The stock was sold at an average price of $11.95, for a total value of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $12.03, for a total value of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00.

Alphatec Price Performance

Alphatec stock opened at $10.46 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.51 billion, a P/E ratio of -8.17 and a beta of 1.39. The firm has a fifty day moving average of $10.88 and a 200-day moving average of $8.56. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $14.88.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Institutional Trading of Alphatec

Several institutional investors have recently added to or reduced their stakes in ATEC. R Squared Ltd bought a new position in Alphatec during the 4th quarter worth approximately $29,000. Comerica Bank grew its position in shares of Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 1,248 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 4,234 shares during the last quarter. Quarry LP raised its holdings in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after buying an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC acquired a new stake in Alphatec in the 4th quarter valued at approximately $50,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ATEC has been the subject of a number of research reports. Piper Sandler boosted their price objective on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Barclays lifted their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. Finally, StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.